Rigor in a research setting is the rigor of method. Hypothesis, design, control, measurement, replication. The work is to produce findings — and the rigor is what separates a finding from a guess. Rigor in a house of formulations is a different rigor. It does not produce findings. It receives them — from a field that has been engaging with longevity, with healthy aging, with the molecular conversation around how a human body holds together over time. The work of the house is what comes next.

What comes next is reading. Reading the literature where the literature has weight, attending to where the field has engaged substantially, where the engagement is more recent, and where the literature is sparse and the practice draws instead on its own accumulated view. Reading the compound through its documentation — what it is, what it is not, where it came from, by whose hands. Reading the dose at which a finding was held and the dose at which a formulation calls for it. Reading the architecture into which a compound will be composed. The rigor of a house is the rigor of how all of this is read.

It is editorial rigor. It is operational rigor. It is compositional rigor. And it does not announce itself. Rigor is felt in the result. Declared by no one. What Codeage puts its name to is what Codeage has held to the standard — and the standard is articulated not by what is asserted of a formulation, but by the discipline that produced it. This is the work The Selection describes. This page describes the rigor inside the work.

The longevity field is, by now, a substantial body of work. Decades of peer-reviewed research across cellular biology, mitochondrial function, metabolic regulation, structural integrity of connective tissue, the architecture of the gut, the chemistry of sleep, the biology of the brain. For some compounds, the field has engaged across many years and many groups — vitamin D, omega-3 fatty acids, magnesium, coenzyme Q10, the conversation extends back well before longevity was named as a category. For others — NAD+ precursors such as nicotinamide mononucleotide, spermidine, senotherapeutic compounds — the engagement is more recent, and the conversation is still developing. For others still, the literature is sparse, and the compound is held instead within the practice's own view of the catalogue.

Selection at Codeage is informed by what the field has examined, where the field has spoken. Where the literature is substantial, the practice draws on the breadth of the work — the lines of inquiry that have replicated, the parameters that have been examined, the mechanisms the field has described. Where the literature is more recent, the practice attends to the conversation as it forms — what is being learned, with what caution, and how the work fits the broader architecture of what the field has examined before. Where the literature is sparse, the practice acknowledges the sparseness, and the compound is considered against the practice's own accumulated view across the catalogue — not asserted as something the field has settled when it has not. Knowing the literature is not the same as knowing a finding. The literature is the conversation; the work is to read the conversation where the conversation exists.

This engagement does not require a dedicated reading function within the company; it is part of how composition itself proceeds. When a compound is considered for a formulation, the literature around it — where it exists — is examined for what it has reported, with what consistency, at what doses, under what parameters. When a formulation is composed, the field's findings inform the choices around dose, around companions, around structure. The reading does not exist apart from the work. It is part of the work, brought to bear where the work calls for it. The depth of what informs a selection is what allows the selection to be more than a list of names — which compound belongs where, at what dose, alongside which companions, and in relation to what the field has described where the field has spoken.

This is the first dimension of rigor: attending to what the literature around a compound contains, where the literature has spoken — and acknowledging where it has not.

Before a compound enters a formulation, documentation around it is gathered and reviewed. This is not paperwork attached to the work; it is part of how the practice knows what it is composing with. Compounds enter the catalogue with different bodies of work behind them — some substantial, some recent, some particular to the practice's own view. The literature, where it speaks, is a separate consideration. Documentation answers a different question, regardless of how much research surrounds the compound: whether the particular compound, drawn from a particular source, by a particular supplier, in a particular batch, is the ingredient it is described to be. This is a question the documentation can address whether the surrounding literature is substantial, recent, or sparse — and addressing it is the foundation the work is built upon.

This architecture is what separates an ingredient from a name. The name appears on a label. The architecture sits beneath it — examinable, documented, archived. Selection cannot rest on what is written above the line. Selection rests on what is held below it.

This is the second dimension of rigor: the rigor of the evidence that surrounds a compound before composition begins.

Documentation establishes what an ingredient is described to be. Verification establishes that the description holds. The two are not the same step. An ingredient can arrive with a certificate of analysis that is impeccable on paper and still require examination — because what arrived is not the certificate; what arrived is a container of compound, and the practice's standard is that what is in the container is what the certificate describes.

The verification chain begins at the supplier. Supplier qualification is the discipline of examining who the practice will source from — their facilities, their certifications, their history with the compound under consideration, the standards they hold themselves to, the documentation they are able to produce on request. A supplier who cannot answer the practice's questions, or who answers them inconsistently, does not become part of the chain. The decision is made before the first batch arrives, and revisited continuously.

For each batch the chain delivers, a certificate of analysis accompanies the compound — identity, purity, microbial parameters, the analytical results that demonstrate the batch meets the specification it was sold against. Documentation is required. It is not sufficient. The practice's standards include independent verification, performed at third-party laboratories where the formulation calls for it, so that the description of the batch and the reality of the batch are held against each other.

Traceability runs the length of the chain. The compound that enters a formulation can be examined back to its supplier, to its batch, to the certificates that accompanied it. The architecture is built so that no link is held in only one place. This is what allows a formulation to be examined — not only at the point of release, but anywhere along the line from source to bottle.

The verification chain is what allows the practice to say, of every compound in every formulation, that it has been examined — that the ingredient list is not a list of names but a list of compounds whose identities, purities, provenances, and specifications have been documented, verified, and archived. This is the work that does not appear on the bottle. It is the work that lives behind the bottle, and that the bottle is built upon.

This is the third dimension of rigor: the rigor of verifying that the documentation and the compound are continuous with each other.

A compound at one dose participates in a formulation in one way. A compound at a different dose participates differently. The dose is part of the compound, not a number appended to it. Selection at Codeage attends to the dose with the same care it attends to the compound itself — because deciding which compound to use and deciding how much of it to use are not two decisions. They are one.

For vitamins and minerals, the field has developed considered ranges over many years of work. Recommended Dietary Allowances. Adequate Intakes. Tolerable Upper Intake Levels. The Dietary Reference Intakes published by the National Academies are part of the literature the practice reads continuously. So are the bodies of work behind them — the long conversation the field has held about appropriate amounts of established compounds across populations and life stages. Selection attends to where, within these ranges, a particular formulation should sit, and why. The decision is made formulation by formulation, in relation to what the architecture calls for.

For other compounds — those whose conversation in the field is more recent, or whose work is more particular — the dose is decided with the same attention but a different process. The literature is read for the doses at which findings have been held, and the parameters around which the conversation has formed. The practice's own accumulated view, drawn from sustained engagement with the catalogue, informs how the dose is composed in relation to companion ingredients. Where the formulation places the compound within an architecture, what role the architecture calls for the compound to occupy — these inform the dose with as much weight as any external source.

What remains constant is that the dose is considered. It is held to the same examination as the compound. It is documented as carefully. And it is part of what selection produces — not the residue of a decision made elsewhere, but the decision itself, articulated in its full form.

This is the fourth dimension of rigor: the rigor of precision in quantity.

Below the discipline of selection is an operational floor. Codeage formulations are manufactured in cGMP-certified facilities — current Good Manufacturing Practice, the framework articulated by the Food and Drug Administration for the category, supplemented by the practices the field has developed beyond what the framework requires. The floor is not where the work begins. It is where the work cannot go below.

cGMP brings with it a discipline of documentation. Master Manufacturing Records held for each formulation. Quality Control functions distinct from production functions, so that the work of making and the work of verifying are held by different hands. Process controls. Equipment qualification. Personnel training. Sanitation. Environmental monitoring. The structure exists so that a formulation produced today can be examined in its full lineage tomorrow — what went into it, by whom, under what conditions, with what results at each step.

Beyond cGMP, the practice attends to third-party verification where the formulation calls for it — laboratories independent of the supply chain that examine the work the supply chain has produced. The architecture is built so that the practice's word is not the only word in the room. Documentation can be checked. Compounds can be tested. Certificates can be verified. The standards held continuously are the standards that can be examined continuously.

Above the operational floor sits the work of formulation — the selection, the composition, the discipline articulated across The Selection, The Blends, The Forms, and The Manufacture. The floor does not produce the formulation. The work above it does. But the work above the floor stands because the floor is held.

This is the fifth dimension of rigor: the rigor of the standards that do not move.

Rigor that is announced is not quite rigor. The practice that calls attention to its discipline at every turn is, often, calling attention to it because the discipline is uncertain. Rigor held at the level a house of formulations should hold it does not need to announce itself. It is felt in the result. It is examinable by anyone who chooses to examine it. It is articulated quietly, in pages such as this one, for those who care to read.

What the practice puts its name to is what the practice has held to the standard. The catalogue is built one formulation at a time, each formulation passing through the discipline this page describes. No formulation enters the catalogue that has not. The reading of the literature, the architecture of evidence, the verification chain, the precision of dose, the operational floor — all are held to every formulation. The catalogue is the record of the discipline, formulation by formulation, year by year.

This is what distinguishes a house from a label. A label asserts. A house demonstrates. The institution is the asset — and the institution is held together not by claims but by the standards the institution holds itself to. Selection is where the standards begin. The work this page describes is what makes selection more than a word. It is what makes Codeage a house, and the catalogue a body of work.

This is the sixth dimension of rigor, the one that holds the others together: the rigor of a discipline sustained over time.